1. Home
  2. RM vs PEPG Comparison

RM vs PEPG Comparison

Compare RM & PEPG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Regional Management Corp.

RM

Regional Management Corp.

HOLD

Current Price

$37.31

Market Cap

396.7M

Sector

Finance

ML Signal

HOLD

Logo PepGen Inc.

PEPG

PepGen Inc.

HOLD

Current Price

$5.58

Market Cap

317.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
RM
PEPG
Founded
1987
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Finance: Consumer Services
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
396.7M
317.6M
IPO Year
2012
2022

Fundamental Metrics

Financial Performance
Metric
RM
PEPG
Price
$37.31
$5.58
Analyst Decision
Hold
Strong Buy
Analyst Count
1
6
Target Price
$30.00
$9.50
AVG Volume (30 Days)
52.1K
763.9K
Earning Date
11-05-2025
11-12-2025
Dividend Yield
3.21%
N/A
EPS Growth
71.26
N/A
EPS
4.13
N/A
Revenue
$610,145,000.00
N/A
Revenue This Year
$16.06
N/A
Revenue Next Year
$6.56
N/A
P/E Ratio
$9.04
N/A
Revenue Growth
9.60
N/A
52 Week Low
$25.41
$0.88
52 Week High
$46.00
$6.85

Technical Indicators

Market Signals
Indicator
RM
PEPG
Relative Strength Index (RSI) 44.65 54.02
Support Level $35.93 $5.41
Resistance Level $39.68 $6.72
Average True Range (ATR) 1.45 0.56
MACD 0.10 0.03
Stochastic Oscillator 37.15 42.63

Price Performance

Historical Comparison
RM
PEPG

About RM Regional Management Corp.

Regional Management Corp is a diversified consumer finance company that provides installment loan products to customers with limited access to consumer credit from banks, thrifts, credit card companies, and other lenders. It is engaged in consumer finance. The company has the core products which are small and large installment loans. The company also offers optional payment and collateral protection insurance. The company's principal source of revenue is interest and fee income on outstanding loans.

About PEPG PepGen Inc.

PepGen Inc is a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapeutics to transform the treatment of severe neuromuscular and neurologic diseases. The company has developed its Enhanced Delivery Oligonucleotide platform to improve the uptake and activity of conjugated oligonucleotide therapeutics. Its EDO peptides are engineered to optimize tissue penetration, cellular uptake, and nuclear delivery, and in preclinical studies, it is observed their ability to transport oligonucleotides into a broad range of target tissues, including smooth, skeletal, and cardiac muscle and the central nervous system. Its pipeline products are; PGN-EDO51, PGN-EDODM1, and others including PGN-EDO53 and PGN-EDO45.

Share on Social Networks: